NF-kB proteins normally exist as latent cytoplasmic complexes, but they can be rapidly activated in response to signals elicited from diverse immune receptors, including the pattern-recognition receptors on innate immune cells and the antigen receptors on lymphocytes. 4, 5 Upon activation, NF-kB moves to the nucleus and participates in the induction of numerous genes, including those encoding pro-inflammatory cytokines, chemokines and cell adhesion molecules, which are important for the establishment of inflammation during the early phase of an infection. Although inflammation is a crucial immune mechanism against infections, inappropriately controlled inflammation contributes to the pathogenesis of immunological diseases. Thus, the NF-kB signaling pathway is subject to tight control by both positive and negative regulatory mechanisms. 6 An important mechanism of NF-kB regulation is protein ubiquitination, 7 which, like protein phosphorylation, has emerged as one of the most fundamental mechanisms of signal transduction. 8 Originally linked to proteasomal degradation, ubiquitination is now being appreciated as a signal transduction mechanism that mediates both degradative and non-degradative cellular processes. 9, 10 The complexity and specificity of ubiquitination are emphasized by the identification of more than 600 potential E3s in the human genome, which surpasses the number of protein kinases. 11 Like phosphorylation, ubiquitination is a reversible process with the reverse reaction being catalyzed by the family of deubiquitinases or deubiquitinating enzymes (DUBs). 12 An increasing number of E3s and DUBs have been assigned to the NF-kB signaling pathways, although only some of them have been characterized in depth by genetic approaches. There is no doubt that E3s and DUBs represent attractive candidates to be exploited as new therapeutic targets in the treatment of immunological disorders and cancer.
This special issue of Cellular and Molecular Immunology presents four expert reviews that discuss the recent progress regarding innate immune receptor signaling, focusing on ubiquitination and NF-kB activation. Kingeter and Lin will discuss NF-kB activation by the Ctype lectin receptors (CLRs), an emerging family of pattern-recognition receptors that recognize microbial carbohydrates and transduce signals via immunoreceptor tyrosine-based activation motifs. Analogous to the antigen receptors, the CLRs activate the IkB kinase by inducing IkB kinase ubiquitination via the CARD9-BCL10-MALT1 complex as well as IkB kinase phosphorylation through an unknown kinase. Since the CLR family includes many members whose ligands remain to be defined, it is anticipated that future studies will lead to important findings regarding the functions of CLRs. Two reviews focus on the mechanisms by which ubiquitination regulates NF-kB activation and immune receptor signaling. Jin and colleagues will discuss a newly characterized family of E3s, termed Peli (or Pellino), which mediates Toll-like receptor signaling in innate immune cells as well as regulates T-cell tolerance in the adaptive immune system. Shembade and Harhaj will focus on A20, a DUB with pivotal roles in the regulation of NF-kB signaling and inflammation. The recent linkage of A20 with human inflammatory and autoimmune diseases, as well as lymphoid malignancies, emphasizes the important function of A20 in the regulation of immune receptor signaling. Finally, Li and colleagues will present us with an example of how tight control of NF-kB and related signaling pathways ensures proper regulation of inflammation in respiratory infections. We sincerely hope that these reviews will offer the readers both the background knowledge and the current information in this rapidly developing area of Immunology research.
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